10 employees
Provasculon develops novel forms of stromal cell-derived factor-1 for the treatment of cardiovascular diseases and diabetic ulcers.
2007
$6M
from 3 investors over 3 rounds
Provasculon raised $1.3M on November 9, 2011
Investors: Broadview Ventures Inc
Provasculon raised $6M on March 24, 2008
Investors: Mass General Brigham and Biogen Idec